The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer.
David G. McLeod
No relevant relationships to disclose
George W. Adams
No relevant relationships to disclose
Marc C. Gittleman
No relevant relationships to disclose
David L. Bihartz
No relevant relationships to disclose
Richard B. Reiling
No relevant relationships to disclose
Henry E. Ruiz
No relevant relationships to disclose
James S. Cochran
No relevant relationships to disclose
Gary Karlin
No relevant relationships to disclose
Julie Prettyman
Disclosure not yet available
Alain Delcayre
Stock Ownership - BN ImmunoTherapeutics
Fatema Legrand
Stock Ownership - BNIT
Wayne Godfrey
Stock Ownership - Bavarian Nordic
Wayne R. Godfrey
Stock Ownership - Bavarian Nordic
Fatema A. Legrand
No relevant relationships to disclose
Grace Mann
Stock Ownership - BN ImmunoTherapeutics
Olga Bandman
Stock Ownership - BN ImmunoTherapeutics